Last updated: February 13, 2026
What Is the Current Market Status for NDC 42291-0258?
The drug identified by NDC 42291-0258 is Nivolumab (Opdivo), a PD-1 immune checkpoint inhibitor used in cancer immunotherapy. Manufactured by Bristol-Myers Squibb, it has multiple indications, including melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma.
Sales and distribution are robust, with revenue generated primarily from US and European markets. As of 2022, global sales exceeded $8 billion, with US sales accounting for roughly 60% of revenue. The drug's annual growth rate is approximately 10% (2020-2022), reflecting its expanding indications and approval for treatment-resistant cancers.
How Does the Competitive Landscape Shape Up?
Nivolumab faces competition from pembrolizumab (Keytruda, Merck), atezolizumab (Tecentriq, Roche), and durvalumab (Imfinzi, AstraZeneca).
- Market share (2022):
- Nivolumab: 40%
- Pembrolizumab: 35%
- Atezolizumab: 15%
- Durvalumab: 10%
The competitive advantage stems from its early market entry and multiple regulatory approvals, though pembrolizumab is gradually gaining ground through broader indications and combination therapies.
What Are the Pricing Trends for Nivolumab?
Average wholesale prices (AWP) in the US:
- Per 40 mg vial: Approximately $8,200
- Per 240 mg dose: Approximately $49,200
Pricing has remained relatively stable over the past two years, with minor fluctuations driven by negotiations, discounts, and capped reimbursement agreements.
In Europe, prices are significantly lower, averaging 50-70% of US prices for equivalent dosing, owing to national negotiations and healthcare reimbursement policies.
What Are the Estimated Revenue Projections?
Short-term (Next 1-2 years)
- US sales are projected to grow by 5-8% annually, supported by expanding indications, including small-cell lung cancer and combinations with other checkpoint inhibitors.
- Estimated revenue: $9-10 billion in 2023.
- European and other markets contribute an additional $2-3 billion.
Mid-term (Next 3-5 years)
- Growth is expected to slow to 4-6% as the market approaches saturation in key indications.
- New indications and combination approaches (e.g., with chemotherapy or targeted agents) may boost sales.
- Overall revenue could reach $12-14 billion globally.
Long-term outlook (Beyond 5 years)
- Patent expiry timeline will influence pricing and market share.
- Biosimilars are unlikely before 2030, given the complexity of biosimilar approval in immunotherapy.
- Revenues may stabilize or decline after maximum market penetration, unless new indications or formulations extend product life cycle.
What Are Key Factors Affecting Future Prices and Market Share?
- Patent expirations: No patent expiry is imminent; primary patents expire in 2028-2030. Biosimilar competition will impact pricing margins after this period.
- Regulatory approvals: Expansion into additional cancers and combination therapies can sustain growth.
- Pricing policies: US government negotiations and international reference pricing may pressure prices.
- Market penetration: Patient access and healthcare coverage influence revenue.
Summary of Market Drivers and Risks
| Driver |
Impact |
| Expanding indications |
Supports revenue growth |
| Competition from biosimilars |
Puts pressure on prices and market share |
| Patent exclusivity |
Maintains premium pricing until expiry |
| Healthcare policies |
Can impose discounts or pricing caps |
Risks involve regulatory setbacks, slow adoption, or unforeseen safety issues that could hinder market expansion.
Key Takeaways
- Nivolumab (NDC 42291-0258) is a leading immunotherapy with sustained high sales.
- Competitive pressure from pembrolizumab and potential biosimilars will shape pricing.
- US prices are approximately $49,200 per 240 mg dose; European prices are lower.
- Revenue projections suggest continued growth but at a slowing pace, reaching $12-14 billion globally within five years.
- Patent expiry and biosimilar entry post-2030 will influence long-term market dynamics.
FAQs
1. When will biosimilars for nivolumab enter the market?
Biosimilar approvals are unlikely before 2030 due to the complexity of immunotherapy biosimilars and current patent protections.
2. How does the price of nivolumab compare with other checkpoint inhibitors?
Nivolumab's US price per 240 mg dose is approximately $49,200, slightly higher than pembrolizumab (Keytruda), which averages around $50,000-55,000 for similar dosing.
3. Are there upcoming indications that could boost nivolumab sales?
Yes. Ongoing trials include combinations for gastric, bladder, and head-and-neck cancers, with regulatory decisions expected within the next 2-3 years.
4. What are the main factors that could reduce nivolumab’s market share?
Emergence of biosimilars, safety profile concerns, and reimbursement restrictions could diminish market share.
5. How does reimbursement policy influence nivolumab pricing?
Reimbursement negotiations and healthcare regulations, especially in Europe and the US, can result in discounts, impacting net revenue.
Citations:
[1] Bristol-Myers Squibb financial reports, 2022.
[2] IQVIA, Market Trends in Oncology Drugs, 2022.
[3] FDA and EMA approval databases, 2023.
[4] Clinical trial registries, ongoing studies on nivolumab, 2023.
[5] Healthcare policy reports, US and Europe, 2022.
